New oryginal generic technologies: A Polish R&D strategic implementation programme - Publication - Bridge of Knowledge

Search

New oryginal generic technologies: A Polish R&D strategic implementation programme

Abstract

Polands's pharmaceutical industry is of great significance to the whole economy. According to Forbs (2 October 2012), the cost of launching a new drug varies from USD 1 to 11 bilion. There is little Chance of a Polish pharmaceutical company developing an original drug due to financial reason.Many research teams in Poland take up research projects aimed at new biologically active compounds. But such an objective has no broader perspective, because the Polish pharmaceutical industry lacks sufficient resources for tests and the registration and promotion of the original drug;. Therefore, such projects will remain purely academic. If commercialized, the result may be, at best, selling the patent rights to a large foreign company for a relatively small amount of money. That is why Polish manufacturers reach for cheaper equivalents of original drugs - generics.

Cite as

Full text

full text is not available in portal

Keywords

Details

Category:
Articles
Type:
artykuły w czasopismach
Published in:
Polish Market pages 34 - 35,
ISSN: 1427-0978
Language:
English
Publication year:
2015
Verified by:
Gdańsk University of Technology

seen 51 times

Recommended for you

Meta Tags